Skip to main content
Evidence Snapshot

Spike glycoprotein

CHEMBL4662936 SINGLE PROTEIN Severe acute respiratory syndrome coronavirus 2
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:54:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4662936
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Spike glycoprotein as ChEMBL target CHEMBL4662936, mapped to UniProt P0DTC2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Spike glycoprotein
SINGLE PROTEIN · Severe acute respiratory syndrome coronavirus 2
As of 2026-09-13
ChEMBL target ID
CHEMBL4662936
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P0DTC2
Spike glycoprotein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Spike glycoprotein matters

As of 2026-09-13

Spike glycoprotein is reviewed as Spike glycoprotein (UniProt P0DTC2); Spike glycoprotein shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.; 18 linked drugs keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 77 compounds, and 49 assays, with lead potency reaching pChEMBL 10.5.

Disease context
COVID-19

Spike glycoprotein shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 18 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ADENOVIRUS TYPE 26 ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN, ADINTREVIMAB, AMUBARVIMAB.

Start review with COVID-19 because it currently carries approved-linked support. Linked drugs include ADENOVIRUS TYPE 26 ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN, ADINTREVIMAB, AMUBARVIMAB, BAMLANIVIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 18 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 77 compounds, and 49 assays for this target. The dominant activity type is KD. CHEMBL5088895 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL5088895 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Spike glycoprotein matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P0DTC2, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why COVID-19 is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

77
Total Compounds
49
Total Assays
3
Approved Drugs
IC50: 15.0, KI: 1.0, EC50: 2.0, KD: 50.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5088895
 10.5 Kd —
No preferred name
CHEMBL5088125
 7.9 Kd —
No preferred name
CHEMBL4869623
 7.6 Kd —
No preferred name
CHEMBL5079992
 7.5 Kd —
No preferred name
CHEMBL5085069
 7.5 Kd —

Approved Drugs

Structure Compound First Approval
CHLOROQUINE
CHEMBL76
 1949
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:54:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4662936